TABLE 1.
Demographics, disease characteristics, and lipid concentration data
| GBA −/PD− | GBA +/PD− | GBA −/PD+ | GBA +/PD+ | P value a | |
|---|---|---|---|---|---|
| n | 20 | 20 | 20 | 20 | |
| Sex (male/female) | 10/10 | 10/10 | 10/10 | 10/10 | |
| Age, y | 71.1 (9.1) | 59.8 (9.2) | 65.9 (12.8) | 66.2 (9.5) | 0.010 |
| AAO | N/A | N/A | 59.4 (14.2) | 60.6 (9.6) | 0.756 |
| Education, y | 16.6 (3.1) | 18 (3.5) | 16.4 (3.5) | 16.4 (2.7) | 0.329 |
| MoCA score | 26.6 (3.1) | 26.5 (1.8) | 24.9 (3.2) | 25.1(2.9) | 0.108 |
| UPDRS III score | 16.0 (8.3) | 15.8 (7.7) | 0.944 | ||
| LEDD | 593 (560) | 447 (359) | 0.332 | ||
| Glucosylsphingosine d18:1 | 0.48 (0.14) | 0.73 (0.20) | 0.50 (0.14) | 0.82 (0.24) | <0.001 |
| Total glucosylceramides | 2443.75 (706.45) | 3217.22 (814.86) | 2910.08 (1030.44) | 2701.03 (1139.59) | 0.071 |
| Total ceramides | 3038.51 (1554.18) | 2338.91 (876.27) |
2719.79 (1260.67) |
2350.19 (1148.74) |
0.228 |
| Glucosylcholesterol | 165.92 (178.04) | 99.33 (63.37) | 116.45 (80.43) | 130.16 (148.91) | 0.401 |
| Total galactosylceramides | 323.08 (110.55) | 387.35 (154.74) | 341.73 (144.46) | 324.25 (81.96) | 0.341 |
| Galactosylsphingosine d18:1 | 0.11 (0.05) | 0.13 (0.07) | 0.13 (0.06) | 0.14 (0.08) | 0.417 |
Values are presented as mean (standard deviation). Data were analyzed by one‐way ANOVA. Participants were grouped by the presence or absence of either Parkinson's disease (PD− or PD+) or the GBA1 N370S mutation (GBA − or GBA +).
a
P value represents overall effect by ANOVA.
AAO, age at motor onset; MoCA, Montreal Cognitive Assessment; UPDRS III, Unified Parkinson's Disease Rating Scale, Part III; LEDD, levodopa‐equivalent daily dose; N/A, not applicable.